Aytu Biopharma, Inc.
AYTU
$2.39
$0.0954.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 69.22M | 64.80M | 67.32M | 68.57M | 81.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.22M | 64.80M | 67.32M | 68.57M | 81.32M |
| Cost of Revenue | 21.01M | 19.03M | 17.74M | 17.93M | 24.76M |
| Gross Profit | 48.21M | 45.77M | 49.59M | 50.64M | 56.57M |
| SG&A Expenses | 40.90M | 41.78M | 42.07M | 43.68M | 46.68M |
| Depreciation & Amortization | 4.07M | 4.07M | 4.06M | 4.07M | 3.96M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.13M | 67.47M | 66.48M | 68.44M | 77.59M |
| Operating Income | 1.10M | -2.68M | 848.00K | 127.00K | 3.74M |
| Income Before Tax | 1.78M | -3.81M | -2.79M | -11.76M | -10.30M |
| Income Tax Expenses | 695.00K | 1.34M | 2.40M | 2.00M | 1.30M |
| Earnings from Continuing Operations | 1.08 | -5.15 | -5.19 | -13.76 | -11.60 |
| Earnings from Discontinued Operations | 558.00K | -95.00K | -1.06M | -2.09M | -2.09M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.64M | -5.24M | -6.25M | -15.84M | -13.68M |
| EBIT | 1.10M | -2.68M | 848.00K | 127.00K | 3.74M |
| EBITDA | 7.13M | 3.57M | 7.54M | 7.24M | 11.02M |
| EPS Basic | 0.20 | -0.97 | -1.14 | -2.86 | -2.64 |
| Normalized Basic EPS | 0.80 | 0.24 | 0.22 | -0.86 | -0.84 |
| EPS Diluted | -1.04 | -1.76 | -1.54 | -2.87 | -2.64 |
| Normalized Diluted EPS | 0.58 | 0.11 | 0.15 | -0.86 | -0.84 |
| Average Basic Shares Outstanding | 23.95M | 23.35M | 22.74M | 22.15M | 20.68M |
| Average Diluted Shares Outstanding | 31.41M | 28.74M | 25.77M | 22.15M | 20.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |